Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Common Equity (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Common Equity for 7 consecutive years, with $303.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 46.96% year-over-year to $303.1 million, compared with a TTM value of $303.1 million through Dec 2025, down 46.96%, and an annual FY2025 reading of $303.1 million, down 46.96% over the prior year.
  • Common Equity was $303.1 million for Q4 2025 at Keros Therapeutics, down from $703.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $728.9 million in Q1 2025 and bottomed at $211.2 million in Q2 2022.
  • Average Common Equity over 5 years is $381.5 million, with a median of $314.7 million recorded in 2023.
  • The sharpest move saw Common Equity soared 1098.8% in 2021, then plummeted 46.96% in 2025.
  • Year by year, Common Equity stood at $243.2 million in 2021, then grew by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then crashed by 46.96% to $303.1 million in 2025.
  • Business Quant data shows Common Equity for KROS at $303.1 million in Q4 2025, $703.6 million in Q3 2025, and $706.7 million in Q2 2025.